Jump to main content.

Oral Dosage Form New Animal Drugs; Cefpodoxime Proxetil Tablets

Note: EPA no longer updates this information, but it may be useful as a reference or resource.

 [Federal Register: August 30, 2004 (Volume 69, Number 167)]
[Rules and Regulations]
[Page 52814-52815]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr30au04-4]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
 
Oral Dosage Form New Animal Drugs; Cefpodoxime Proxetil Tablets

AGENCY:  Food and Drug Administration, HHS.
ACTION:  Final rule.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of a new animal drug application 
(NADA) filed by Pharmacia and Upjohn Co. The NADA provides for 
veterinary prescription use of cefpodoxime proxetil tablets in dogs for 
treatment of skin infections (wounds and abscesses) caused by 
susceptible strains of certain bacteria.

DATES:  This rule is effective August 30, 2004.

FOR FURTHER INFORMATION CONTACT:  Melanie R. Berson, Center for 
Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-7540, e-mail: 
melanie.berson@fda.gov.

SUPPLEMENTARY INFORMATION: Pharmacia and Upjohn Co., 7000 Portage Rd., 
Kalamazoo, MI 49001-0199, filed NADA 141-232 for use of SIMPLICEF 
(cefpodoxime proxetil) Tablets. The NADA provides for veterinary 
prescription use of cefpodoxime proxetil tablets in dogs for treatment 
of skin infections (wounds and abscesses) caused by susceptible strains 
of Staphylococcus intermedius, S. aureus, Streptococcus canis (group G, 
[bgr]-

[[Page 52815]]

hemolytic), Escherichia coli, Pasteurella multocida, and Proteus 
mirabilis. The NADA is approved as of July 22, 2004, and the 
regulations are amended in part 520 (21 CFR part 520) by adding Sec.  
520.370 to reflect the approval. The basis of approval is discussed in 
the freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    Under section 512(c)(2)(F)(i) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(i)), this approval qualifies for 
5 years of marketing exclusivity beginning July 22, 2004.
    FDA has determined under 21 CFR 25.33(d)(1) that this actions is of 
a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor environmental impact statement is required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 520

    Animal drugs.

? Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

? 1. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority:  21 U.S.C. 360b.

? 2. Section 520.370 is added to read as follows:

Sec.  520.370   Cefpodoxime tablets.

    (a) Specifications. Each tablet contains cefpodoxime proxetil 
equivalent to 100 or 200 milligrams (mg) cefpodoxime.
    (b) Sponsors. See No. 000009 in Sec.  510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. 5 to 10 mg per kilogram 
(2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 
to 3 days beyond the cessation of clinical signs, up to a maximum of 28 
days.
    (2) Indications for use. For the treatment of skin infections 
(wounds and abscesses) caused by susceptible strains of Staphylococcus 
intermedius, S. aureus, Streptococcus canis (group G, [bgr]-hemolytic), 
Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
    (3) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

    Dated: August 17, 2004.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 04-19654 Filed 8-27-04; 8:45 am]
BILLING CODE 4160-01-S

 
 

Local Navigation

Jump to main content.